PRRT2 and breast carcinoma: The protein kinase C (PKC) inhibitor sotrastaurin was active against ER-positive T-47D luminal breast cancer cells by downregulation of the ER effector MYB, suggesting a promising role of MYB inhibition in the prevention and treatment of tamoxifen-resistant ER-positive breast cancers[179].